<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03163238</url>
  </required_header>
  <id_info>
    <org_study_id>IRB000087632</org_study_id>
    <nct_id>NCT03163238</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine and the Inflammatory Response in Pediatric Cardiac Surgery</brief_title>
  <official_title>The Effect of Dexmedetomidine on the Inflammatory Response in Children Under Congenital Heart Disease Repair With Cardiopulmonary Bypass: A Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiopulmonary bypass-assisted surgery initiates a systemic inflammatory response induced by
      extrinsic (e.g. anesthesia, contact activation within the extracorporeal circuit,
      endotoxemia) and intrinsic (e.g. tissue damage, endothelial cell activation,
      ischemia-reperfusion injury of myocardium) factors. This may either be mild or lead to a more
      severe clinical condition. Inflammation after pediatric open heart surgery is a parameter
      affecting also duration of mechanical ventilatory support. Dexmedetomidine use was associated
      with a reduced increase in plasma IL-1, IL-6, TNF-a, and INF-g levels
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dexmedetomidine will be used during Cardiopulmonary bypass-assisted surgery for pediatric
      cardiac surgery
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2017</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infilamatory response</measure>
    <time_frame>Within the first 24 hours</time_frame>
    <description>Interleukin 6 and 10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sedation score</measure>
    <time_frame>Within the first 24 hours</time_frame>
    <description>Special scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of mechanical ventilaton</measure>
    <time_frame>Within 7 days</time_frame>
    <description>Length of mechanical ventilaton In days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>Within 7 days</time_frame>
    <description>Length of ICU stay In days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay.</measure>
    <time_frame>Within 7 days</time_frame>
    <description>Length of hospital stay days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cardiac Surgical Procedures</condition>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One syringe contain dexmedetomidine 0.5 mcg/kg diluted with normal saline in Dexmedetomidine group. Second syringe (50 ml) will contain normal saline (0.9%) in addition to Dexmedetomidine in addition to normal saline in Dexmedetomidine group. Concentration of Dexmedetomidine will be diluted according to the body weight so that we will fix the rate of infusion (1 ml/kg) to achieve a concentration of 0.5 mcg/kg/h in Dexmedetomidine group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group S</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One syringe contain normal saline in 5 ml in Saline group. Second syringe (50 ml) will contain normal saline (0.9%) alone in rate of infusion (1 ml/kg) in Saline group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine 0.5 mcg/kg diluted with normal saline in Dexmedetomidine group. Second syringe (50 ml) will contain normal saline (0.9%) in addition to Dexmedetomidine in addition to normal saline in Dexmedetomidine group. Concentration of Dexmedetomidine will be diluted according to the body weight so that we will fix the rate of infusion (1 ml/kg) to achieve a concentration of 0.5 mcg/kg/h in Dexmedetomidine group.</description>
    <arm_group_label>Group D</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>One syringe contain normal saline in 5 ml in Saline group. Second syringe (50 ml) will contain normal saline (0.9%) alone in rate of infusion (1 ml/kg) in Saline group</description>
    <arm_group_label>Group S</arm_group_label>
    <other_name>Saline 0.9</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Elective repair of congenital heart disease with cardiopulmonary bypass Exclusion
        Reintervention surgery requirement for blood products from the start of CPB, preoperative
        intake of corticosteroids, deep hypothermia, those with preoperative low cardiac output,
        those with non-palpable peripheral pulses before surgery (e.g., accompanying coarctation of
        the aorta) or ischemic time during cardiopulmonary bypass more than 90 minutes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sayed K Abd-Elshafy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate profossor of anesthesiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sayed K Abd-Elshafy, MD</last_name>
    <phone>0882293592</phone>
    <email>sayed_k_72@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>mohamed abdelatef, MD</last_name>
      <phone>0020882413201</phone>
      <email>latif_mohamed@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2017</study_first_submitted>
  <study_first_submitted_qc>May 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2017</study_first_posted>
  <last_update_submitted>July 23, 2017</last_update_submitted>
  <last_update_submitted_qc>July 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Sayed Kaoud Abd-Elshafy</investigator_full_name>
    <investigator_title>Associate Profossor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Congenital Heart Disease</keyword>
  <keyword>Cardiopulmonary Bypass</keyword>
  <keyword>Interleukin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

